The Chemours Company reported second quarter 2026 net sales of $1.6 billion, approximately flat year-over-year, while adjusted EBITDA of $247 million came in near the high end of its guidance range and free cash flow improved 128% to $114 million. Net loss attributable to Chemours narrowed to $274 million, or $1.81 per diluted share, from a loss of $380 million, or $2.53 per diluted share, a year earlier, with the prior-year period weighed down by a New Jersey settlement and the current quarter impacted by legal and environmental reserves tied to EPA and WVDEP settlements. Adjusted net income fell to $64 million, or $0.42 per diluted share, from $91 million, or $0.61 per diluted share, partly due to tax impacts from the Kuan Yin property sales. The company paid down €230 million of its B-3 Euro-denominated Term Loan, reducing gross debt to $3.9 billion and net leverage to 4.4 times. For the third quarter, Chemours expects consolidated adjusted EBITDA between $175 million and $205 million, with free cash flow of at least $50 million, and it maintained its full-year 2026 adjusted EBITDA outlook of $775 million to $825 million.
Chemours CoAdjusted EBITDA near guidance high, free cash flow surged 128%, and debt reduced.